Limited Access: Real-World Cellular Therapy Experience in Aggressive Lymphomas and the Underrepresentation of Black Patients

Document Type

Conference Proceeding

Publication Date

4-24-2025

Publication Title

International Journal of Cancer Care and Delivery

Abstract

 

Background: Cellular therapy comprises Chimeric Antigen Receptor (CAR) and Bispecific T-cell Engager (BiTE) therapy. As of June 2024, six CAR-T cell therapies have been approved, demonstrating efficacy in patients with B-cell malignancies and multiple myeloma (1). Still, use of CAR-T has been limited for several reasons including toxicity, cost, patient hesitation, and absence of caregiver support (2). We assess real-life outcomes and referral/treatment patterns of patients at our community center.

Volume

5

Issue

Suppl 1

First Page

S51

Comments

Summit on Cancer Health Disparities (SCHD25), April 25-27, 2025, Seattle, WA

Last Page

S52

DOI

10.53876/001aa.129521

Share

COinS